Drugs / JS014
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06882876 | Jul 2025 → Jan 2027 expected | hepatocellular carcinoma | Xiangya Hospital of Central South University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT05296772 | Feb 2022 → Jun 2024 | cancer, lymphoma | Anwita Biosciences | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06882876 ↗ |
| Modality | Protein / enzyme biologic | “a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody” NCT05296772 ↗ |